ClinicalTrials.gg
CompletedNCT02261220Updated Mar 6, 2020

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of MEDI4736 and tremelimumab in Advanced Solid Tumors, sponsored by MedImmune LLC. Completed at 75 sites in 9 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2020, 6 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
380
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • advanced solid tumors
  • durvalumab
  • tremelimumab
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects
  • 18 years and older
  • Histologic confirmation of advanced solid tumors
  • Subjects must have recurrent/ disease and may have been previously treated in the recurrent/metastatic setting.

Exclusion criteria

Exclusion Criteria:

  • Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment
  • Active or prior documented disease within the past 2 years
  • Current or prior use of medication within 14 days with some exceptions.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    MEDI4736 + Tremelimumab

    Subjects with multiple tumor types.

    Biological: MEDI4736 · Biological: tremelimumab

Interventions

  • BiologicalMEDI4736

    MEDI4736 is administered by IV infusion in combination with tremelimumab

  • Biologicaltremelimumab

    Tremelimumab is administered by IV infusion in combination with MEDI4736

06

What researchers measure

Primary outcomes

  1. Number of subjects reporting adverse events

    Time frame: Screening through 15 months after the last subject enters re-treatment

  2. Number of subjects reporting serious adverse events

    Time frame: Screening through 15 months after the last subject enters re-treatment

  3. Number of subjects experiencing a dose-limiting toxicity

    Time frame: First dose of study medication through 4 weeks after the first dose of study medication

  4. Change from Baseline in laboratory evaluations

    Time frame: Screening through 3 months after the last dose of study medication

  5. Change from Baseline in vital signs

    Time frame: Screening through 3 months after the last dose of study medication

  6. Change from Baseline in electrocardiogram evaluations

    Time frame: Screening through 3 months after the last dose of study medication

  7. Overall Response Rate in Select Tumor Types

    Time frame: First dose of study medication through 15 months after the last subject enters re-treatment

Secondary outcomes

  1. Overall Response Rate

    Time frame: First dose of study medication through 15 months after the last subject enters re-treatment

  2. Disease Control Rate

    Time frame: First dose of study medication through 15 months after the last subject enters re-treatment

  3. Duration of Response

    Time frame: First dose of study medication through 15 months after the last subject enters re-treatment

  4. Progression-Free Survival

    Time frame: First dose of study medication through 15 months after the last subject enters re-treatment

  5. Overall Survival

    Time frame: First dose of study medication through 15 months after the last subject enters re-treatment

  6. Individual MEDI4736 concentrations

    Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication

  7. Individual tremelimumab concentrations

    Time frame: First dose of tremelimumab through 3 months after the last dose of study medication

  8. MEDI4736 area under the concentration-curve

    Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication

  9. Tremelimumab area under the concentration-curve

    Time frame: First dose of tremelimumab through 3 months after the last dose of study medication

  10. Number of subjects that develop detectable antidrug antibodies to MEDI4736

    Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication

  11. Number of subjects that develop antidrug antibodies to tremelimumab

    Time frame: First dose of tremelimumab through 3 months after the last dose of study medication

Other outcomes

  1. Change in Biomarkers

    Time frame: Screening through 3 months following the last dose of study medication

07

Study locations

75 sites
  • Research Site
    Scottsdale, Arizona 85258, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Iowa City, Iowa 52242-1008, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    New York, New York 10116, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Houston, Texas 77521, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Angers Cedex 02, 49055, France
  • Research Site
    BESANCON Cedex, 25030, France
  • Research Site
    Bordeaux Cedex, 33075, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Pierre Benite, 69495, France
  • Research Site
    Vandoeuvre les Nancy, 54519, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Kfar Saba, 44410, Israel
  • Research Site
    Tel-Aviv, 64239, Israel
  • Research Site
    Busan, 49241, Korea, Republic of
  • Research Site
    Daegu, 41404, Korea, Republic of
  • Research Site
    Daegu, 42601, Korea, Republic of
  • Research Site
    Gwangju, 61469, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Tilburg, 5042AD, Netherlands
  • Research Site
    Barcelona, 08026, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Glasgow, G12 0YN, United Kingdom
  • Research Site
    London, EC1M 6BQ, United Kingdom
  • Research Site
    London, NW1 2BU, United Kingdom
  • Research Site
    Middlesborough, TS4 3BW, United Kingdom
  • Research Site
    Oxford, OX3 7LE, United Kingdom
  • Research Site
    Wirral, CH63 4JY, United Kingdom
08

References and documents

Publications

  • Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann MD. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 Dec;10(12):1842-1853. doi: 10.1158/2159-8290.CD-20-0047. Epub 2020 Aug 14. PubMed 32816849 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Jan 2020, 63 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 10, 2014
StartActual
Oct 13, 2014
Primary completionActual
Jan 27, 2020
CompletionActual
Jan 27, 2020
Last update
Mar 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02261220
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 10, 2014
Start date
Oct 13, 2014
Primary completion
Jan 27, 2020
Completion
Jan 27, 2020
Last update
Mar 6, 2020

Study contacts

MedImmune LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion